We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
Cap. Flow
-$582M
Cap. Flow %
-24.75%
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$43.9M
2
CGEM icon
Cullinan Oncology
CGEM
+$33.2M
3
INCY icon
Incyte
INCY
+$30M
4
TMO icon
Thermo Fisher Scientific
TMO
+$24.9M
5
ARGX icon
argenx
ARGX
+$23.2M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$139M
2
ALGN icon
Align Technology
ALGN
+$62M
3
BSX icon
Boston Scientific
BSX
+$57.5M
4
LLY icon
Eli Lilly
LLY
+$54.5M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Technology 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
101
Pacific Biosciences
PACB
$422M
– –
-675,000
Closed -$2.53M
RDNT icon
102
RadNet
RDNT
$4.84B
– –
-238,000
Closed -$11.6M
VERA icon
103
Vera Therapeutics
VERA
$2.53B
– –
-383,500
Closed -$16.5M
XFOR icon
104
X4 Pharmaceuticals
XFOR
$372M
– –
-80,433
Closed -$3.35M
KYTX icon
105
Kyverna Therapeutics
KYTX
$481M
– –
-202,333
Closed -$5.03M
ITCI
106
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-600,000
Closed -$239M
FUSN
107
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-6,500,328
Closed -$139M
ALPN
108
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-1,174,700
Closed -$46.6M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2024 Portfolio in Review

As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $582M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.

  • Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
  • Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
  • Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
  • Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
  • Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
  • Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.